AQ Biotech key facts
as of Oct 2026- Developer of a non-invasive health screening and monitoring system designed for early detection of various diseases, particularly urinary tract cancers, starting from prostate cancers.
- AQ Biotech is valued at approximately $11.5M as of Oct 2026 (last reported valuation).
- It has raised $8.6M; the latest was Angel (individual) ($2.4M) in Apr 2025.
- Notable investors include Tekes, Corporatum, Keksintösäätiö, Newentures.
- Status: Privately Held (backing).
AQ Biotech's last reported valuation, Apr 2025. Nothing priced has surfaced since.
- ·Watch AQ Biotech: the Monday email on marks, rounds and moves
AQ Biotech funding rounds
No funding rounds for AQ Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs AQ Biotech
4AQ Biotech valuation
AQ Biotech's last reported valuation was $11.5 million in Apr 2025. No priced round, secondary trade or fund mark has surfaced since.
AQ Biotech investors
4 investors are on record for AQ Biotech, including Tekes, Corporatum, Keksintösäätiö and Newentures.
About AQ Biotech
Developer of a non-invasive health screening and monitoring system designed for early detection of various diseases, particularly urinary tract cancers, starting from prostate cancers. The company's system is responsible for the early detection of oral and prostate cancers along with gastroenterological and infectious diseases as the enhanced TRF (transfer of funds) method provides a quick, accurate, and affordable process for the analysis of biological samples, enabling doctors to have access to non-invasive screening tests for preventive healthcare.
- Sector
- Healthcare
- HQ
- Turku, Finland
- Founded
- 2017
- Employees
- 10
- Website
- aqbiotech.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.